Search

Your search keyword '"M.A. Mouret Reynier"' showing total 6 results
Start Over Author "M.A. Mouret Reynier" Topic breast cancer
6 results on '"M.A. Mouret Reynier"'

1. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database

Author

P. Gougis, M. Carton, C. Tchokothe, M. Campone, F. Dalenc, A. Mailliez, C. Levy, W. Jacot, M. Debled, M. Leheurteur, T. Bachelot, A. Hennequin, C. Perrin, A. Gonçalves, L. Uwer, J.C. Eymard, T. Petit, M.A. Mouret-Reynier, E. Chamorey, G. Simon, M. Saghatchian, C. Cailliot, and C. Le Tourneau

Subjects
Breast cancer, Metastatic recurrence, Growth rate, Real-life data, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Purpose: The Time to First Metastatic Recurrence (TFMR) could be considered as an indirect reflection of the tumour growth kinetics which plays an important role in cancer. Molecular subtypes such as expression of estrogen receptor are known predictive factors of TFMR. The CinéBreast study aimed to identify predictive factors of the time to TFMR. Methods: The French Epidemiological Strategy and Medical Economics (ESME) Metastatic Breast Cancer (MBC) Database (NCT03275311) was used, which contains data from a cohort of metastatic breast cancer patients from 2008 to 2016 using retrospective data collection. It is a national multi-centre database. The impact of TFMR on overall survival (OS) since first metastasis was also evaluated. Results: Among 16 702 patients recorded in the ESME MBC database, 10 595 had an initially localised breast cancer with hormone receptor (HR) and HER2 status available, with a metastatic recurrence. Median follow up was 56 months. Median TFMR was 59 months (120: 24%). HER2+ and TNBC were respectively 4 times and 12 times (p

Published
2020
Full Text
View/download PDF

2. 314P Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane

Author

Gaëtane Simon, C. Levy, Thomas Bachelot, M.A. Mouret Reynier, J.-C. Eymard, Lionel Uwer, A. Vasseur, T. de La Motte Rouge, Luc Cabel, Thomas Grinda, Florence Dalenc, A. Gonçalves, Isabelle Desmoulins, Matthieu Carton, Séverine Guiu, Paule Augereau, Thierry Petit, Laurence Vanlemmens, Marc Debled, and M. Robert

Subjects
Oncology, medicine.medical_specialty, Taxane, Breast cancer, business.industry, Internal medicine, HER2 negative, medicine, Hematology, medicine.disease, Previously treated, business
Published
2021
Full Text
View/download PDF

3. 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting

Author

Isabelle Desmoulins, Thomas Bachelot, Anne Patsouris, Christelle Jouannaud, Amélie Lusque, M. Leheurteur, Audrey Mailliez, J-M Ferrero, Lionel Uwer, J-S. Frenel, Suzette Delaloge, A. Gonçalves, Thierry Petit, Paul-Henri Cottu, C. Levy, M.A. Mouret Reynier, Véronique Diéras, Véronique D'Hondt, O. Villacroux, and O. De Calbiac

Subjects
Oncology, medicine.medical_specialty, Breast cancer, business.industry, Internal medicine, medicine, Hematology, medicine.disease, business, Metastatic breast cancer
Published
2021
Full Text
View/download PDF

4. A multi-center evaluation of clinical pathways cost and time using real-life data in 411 breast cancer patients treated with intravenous versus subcutaneous Trastuzumab

Author

N. Bahmad, J.F. Tournamille, V. Priou, G. Lebozec, N. Perez-staub, C. bernard Marty, R. Alfonsi, M.A. Mouret-reynier, C. Blein, M.C. Borg, H. Attar-rabia, C. Pers-regouby, A. Jaffre, J. Forget, and Z. El Islami

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.disease, Real life data, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, medicine, Center (algebra and category theory), business, medicine.drug
Published
2018
Full Text
View/download PDF

5. Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort

Author

Marc Debled, Paule Augereau, J-M Ferrero, Guillaume Louvel, Thomas Bachelot, J.-D. Fumet, Christine Levy, Julien Fraisse, M. Robain, M.A. Mouret Reynier, C. Courtinard, Florence Dalenc, Christelle Jouannaud, David Pasquier, Etienne Brain, Corinne Veyret, Véronique Diéras, William Jacot, A. Gonçalves, and Amélie Darlix

Subjects
Oncology, medicine.medical_specialty, medicine.anatomical_structure, Breast cancer, business.industry, Internal medicine, Central nervous system, Cohort, Medicine, Hematology, business, medicine.disease
Published
2018
Full Text
View/download PDF

6. PCN95 - A MULTICENTRIC EVALUATION OF CONSUMABLES AND TRANSPORTS COST OF BREAST CANCER PATIENT’S TREATED BY TRASTUZUMAB ACCORDING TO THE ADMINISTRATION FORM (IV VERSUS SC)

Author

V. Priou, R. Alfonsi, G. Lebozec, C. bernard Marty, C. Blein, H. Attar Rabia, J.F. Tournamille, M.A. Mouret-reynier, M.C. Borg, A. Jaffre, N. Bahmad, and N. Perez staub

Subjects
Oncology, medicine.medical_specialty, Consumables, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Breast cancer, Trastuzumab, Internal medicine, medicine, business, Administration (government), medicine.drug
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results